Unlock stock picks and a broker-level newsfeed that powers Wall Street.

TSXV - Free Realtime Quote CAD

XORTX Therapeutics Inc. (XRTX.V)

Compare
1.1500
-0.0500
(-4.17%)
As of 9:30:00 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Dr. Allen Warren Davidoff Ph.D. Founder, CEO, President & Director 385.94k -- 1960
Dr. Stephen Haworth M.D., MRCP Chief Medical Officer 214.67k -- 1950
Dr. Stacy Evans M.B.A., M.D. Chief Business Officer 280k -- 1974
Dr. Michael Scott Bumby D.V.M., M.B.A. Chief Financial Officer -- -- 1964
Nick Rigopoulos Director of Communications -- -- --
Dr. David Sans M.B.A., Ph.D. Director of Corporate Development -- -- 1970
Dr. David MacDonald Ph.D. Consultant of Clinical Operations -- -- 1964
Ms. Charlotte May Corporate Secretary -- -- --

XORTX Therapeutics Inc.

3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
403 455 7727 https://www.xortx.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Corporate Governance

XORTX Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 14, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC

XORTX Therapeutics Inc. Earnings Date

Recent Events

Related Tickers